Back to Authors

Carter, Kelly

0000-0003-1772-9431

Mayo Clinic

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Citations 3

Spatial multi-omics and single-cell transcriptomics uncover senescence-associated cellular programs during colon adenoma to cancer progression
Yu, Ming , Xie, Yumo , Allen, Lena, Carter, Kelly , Donato, Elizabeth , Cheng, Lingxin , Kendziorski, Christina , Hall, Lance T. , Marzo, Angelo M. De , Hicks, Jessica, Reddi, Deepti , Sun, Wei, Matkowskyj, Kristina A , De Marzo, Angelo M , Newell, Evan W , Grady, William M , Carter, Kelly , Reddi, Deepti , Sun, Wei, Grady, William M.

No container title available | August 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.06.743310 Get It

Abstract Colorectal cancer develops through a normal-adenoma-carcinoma sequence, yet only 5-10% of adenomas progress to malignancy, and the cellular programs governing that sequence remain poorly defined. Here we generate a spatial multi-omics atlas of human colon adenomas, combining Visium CytAssist and protein co-detection across 24 nonadvanced and advanced tubular adenomas with single-cell resolution Xenium Prime 5K profiling of 101 patient-matched normal, adenoma, and carcinoma cores from 16 patients. Integrating whole-transcriptome and 31-plex protein data identifies nine spatial clusters and two dysplastic epithelial populations that co-express stemness, proliferation, and senescence programs. These programs occupy a shared, spatially confined epithelial niche that expands from adenoma to carcinoma. Spatial analysis revealed GDF15, a senescence-associated secretory factor, mediated the coupling between senescence and stemness in advanced adenomas, and that GDF15-high epithelium locally excludes CD8+ T cells in adenoma and, more broadly, in carcinoma. These findings position senescence as a spatially instructive rather than merely tumor-suppressive program during colorectal carcinogenesis and suggest GDF15 might be a potential candidate target for cancer prevention and interception in the colon.
Novel DNA Methylation Biomarker Panel for Detection of Esophageal Adenocarcinoma and High-Grade Dysplasia
Yu, Ming , Moinova, Helen , Willbanks, Amber, Cannon, Victoria K., Wang, Ting , Carter, Kelly , Kaz, Andrew M. , Reddi, Deepti , Inadomi, John M. , Luebeck, E. Georg , Iyer, Prasad G. , Wang, Jean S. , Shaheen, Nicholas J. , Thota, Prashanti N., Willis, Joseph , LaFramboise, Thomas , Chak, Amitabh , Markowitz, Sanford D. , Moinova, Helen R , Inadomi, John , Luebeck, Georg , Shaheen, Nicholas J , Chak, Amitabh , Grady, William M , Willis, Joseph E , Carter, Kelly , Cannon, Victoria K., Reddi, Deepti , Canto, Marcia Irene , Grady, William M.

Clinical Cancer Research | July 15, 2022 | Volume: 28 | Issue: 17 | Pages: 3761-3769

10.1158/1078-0432.ccr-22-0445 Get It

Abstract Purpose: Current endoscopy-based screening and surveillance programs have not been proven effective at decreasing esophageal adenocarcinoma (EAC) mortality, creating an unmet need for effective molecular tests for early detection of this highly lethal cancer. We conducted a genome-wide methylation screen to identify novel methylation markers that distinguish EAC and high-grade dysplasia (HGD) from normal squamous epithelium (SQ) or nondysplastic Barrett's esophagus (NDBE). Experimental Design: DNA methylation profiling of samples from SQ, NDBE, HGD, and EAC was performed using HM450 methylation arrays (Illumina) and reduced-representation bisulfate sequencing. Ultrasensitive methylation-specific droplet digital PCR and next-generation sequencing (NGS)-based bisulfite-sequencing assays were developed to detect the methylation level of candidate CpGs in independent esophageal biopsy and endoscopic brushing samples. Results: Five candidate methylation markers were significantly hypermethylated in HGD/EAC samples compared with SQ or NDBE (P < 0.01) in both esophageal biopsy and endoscopic brushing samples. In an independent set of brushing samples used to construct biomarker panels, a four-marker panel (model 1) demonstrated sensitivity of 85.0% and 90.8% for HGD and EACs respectively, with 84.2% and 97.9% specificity for NDBE and SQ respectively. In a validation set of brushing samples, the panel achieved sensitivity of 80% and 82.5% for HGD and EAC respectively, at specificity of 67.6% and 96.3% for NDBE and SQ samples. Conclusions: A novel DNA methylation marker panel differentiates HGD/EAC from SQ/NDBE. DNA-methylation–based molecular assays hold promise for the detection of HGD/EAC using esophageal brushing samples.
Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance)
Symonds, Lynn , Carter, Kelly , Innocenti, Federico , Bosch, Linda J.W. , Meijer, Gerrit A , Carvalho, Beatriz , Zemla, Tyler J, Carter, Kelly , Meijer, Gerrit A , Yu, Ming , Zhang, Yuhong , Ou, Fang‐Shu , Zemla, Tyler , Bertagnolli, Monica M. , Grady, William M. , Cohen, Stacey A.

Epigenetics | April 12, 2022 | Volume: 17 | Issue: 12 | Pages: 1715-1725

10.1080/15592294.2022.2058225 Get It